RBC Capital Keeps Their Buy Rating on Stryker (SYK)

In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Stryker, with a price target of $435.00. The company’s shares closed yesterday at $354.30.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Singh Chadha is a 3-star analyst with an average return of 2.5% and a 51.15% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Dexcom, and Edwards Lifesciences.

In addition to RBC Capital, Stryker also received a Buy from Needham’s Michael Matson in a report issued today. However, on January 26, TD Cowen downgraded Stryker (NYSE: SYK) to a Hold.

Based on Stryker’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $6.06 billion and a net profit of $859 million. In comparison, last year the company earned a revenue of $5.49 billion and had a net profit of $834 million

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in November 2025, William E. Berry, the VP & CAO of SYK sold 1,953.00 shares for a total of $713,801.97.